Federico Mingozzi

Chief Science and Technology Officer
Spark Therapeutics, Inc.
Philadelphia, Pennsylvania, United States

Presentation(s):

• OC 02.4 - Long-Term Follow-Up of Participants in the Phase I/II Trial of Dirloctocogene Samoparvovec (SPK-8011): Durable FVIII Expression and Clinically Meaningful Reduction of Bleeding

  Saturday, June 22, 2024
  13:45 – 14:00 ICT